Mass General Brigham

Mass General Brigham

Early-stage life science venture investor

Overview

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

About Mass General Brigham

Simplify's Rating
Why Mass General Brigham is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Venture Capital

Biotechnology

Healthcare

Company Size

1-10

Company Stage

N/A

Total Funding

$1.7B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fallon Health merger on January 8, 2026 expands health plan reach.
  • Tampa General joint venture on January 12 boosts ambulatory services.
  • $10.3 billion capital plan through 2030 supports innovation pipeline.

What critics are saying

  • $30M AIDIF depleted by Carta Healthcare's $18.25M investment in May 2025.
  • Dana-Farber split in September 2023 dissolves key cancer partnership.
  • NIH 15% funding cuts in 2026 starve hospital research spinouts.

What makes Mass General Brigham unique

  • Proprietary access to Mass General Brigham's research network seeds spinouts.
  • AIDIF launched in 2020 invests in AI/digital health at Series A/B.
  • Seeded three startups for hematologic and musculoskeletal treatments.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1.7B

Above

Industry Average

Funded Over

0 Rounds

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Flexible Work Hours

Remote Work Options

Hybrid Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Family Planning Benefits

Fertility Treatment Support

Professional Development Budget

Conference Attendance Budget

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Stock Options

Company Equity

401(k) Company Match

Parental Leave

Adoption Assistance

Childcare Support

Relocation Assistance

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Meal Benefits

Commuter Benefits

Legal Services

Employee Discounts

Company Social Events

Company News

PR Newswire
Mar 19th, 2026
MGB Home Care clinicians to picket Mass General over stalled contract talks after year of bargaining

Approximately 450 clinicians at Mass General Brigham Home Care, represented by the Massachusetts Nurses Association, will hold an informational picket on 24 March outside Massachusetts General Hospital. The clinicians are seeking their first union contract after more than 20 bargaining sessions since March 2025. The bargaining unit includes registered nurses, occupational therapists, physical therapists, speech language pathologists, social workers and dieticians who voted to join the MNA in June 2024. They are demanding reasonable caseload limits, clear productivity standards, competitive wages and recruitment protections. MGB reported a $59.2 million operating gain in the year ending September 2025, with CEO Dr Anne Klibanski's compensation rising 40% to $8.4 million in 2024. The picket is scheduled for 15:30 to 17:00 and is not a strike.

CityBiz
Oct 7th, 2025
Affinia Therapeutics Secures $40M Series C

Avidity Partners has participated in a $40 million Series C funding round for Affinia Therapeutics, a company specializing in adeno-associated virus (AAV) gene therapies.

Business Wire
Oct 4th, 2025
Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubs...

PR Newswire
May 7th, 2025
Carta Healthcare Secures $18.25M Series B1 Funding

Carta Healthcare has secured $18 million in Series B1 funding to enhance its AI-powered clinical data abstraction and analytics. The investment, led by UPMC Enterprises with participation from several health ventures, will support Carta's growth in the life sciences market. The funding follows Carta's acquisition of Realyze Intelligence and aims to expand its customer base and improve healthcare data management. CEO Brent Dover highlighted the investment's role in scaling operations and product deployment.

Fierce Biotech
Feb 12th, 2025
Sanofi-backed Abcuro raises $200M series C to fund pivotal trial of KLRG1 antibody

Sanofi-backed Abcuro has secured

Recently Posted Jobs

Sign up to get curated job recommendations

Mass General Brigham is Hiring for 1806 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →